Chris Loose

Chris Loose, PhD, is Co-Founder and Chief Executive Officer of Progentos Therapeutics. Previously, Chris served as Frequency Therapeutics’ Chief Scientific Officer since co-founding the company in 2014. Chris led the scientific efforts as Frequency advanced a hearing restoration asset to Phase 2 trials, secured a partnership with Astellas Pharma, and completed an initial public offering. Chris also oversaw the expansion of the research portfolio into remyelination for multiple sclerosis.

​

Before joining Frequency, Chris served as Chief Technology Officer for Semprus BioSciences, a company he also co-founded, which was acquired by Teleflex in 2012. During his tenure at Semprus, he led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA and European CE marketing clearance.

 

Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. Chris was named to the MIT Technology Review 35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. Chris also served as the Executive Director of Yale University’s Center for Biomedical and Interventional Technology (CBIT), and Associate Adjunct Professor of Urology in the Yale School of Medicine.

 

Chris holds a Ph.D. in Chemical Engineering from MIT, where he was a Hertz Fellow and studied under Robert Langer, Sc.D. Previously, he earned a B.S.E in Chemical Engineering summa cum laude from Princeton University.